FDA News will be offering a webinar entitled: "Follow-on Biologics Patent Litigation: Using Additional Patents and REMS to Protect Market Share" on May 27, 2009 from 11:00 am to 12:30 pm (EST). Chad Landmon and Matt Becker of Axinn, Veltrop & Harkrider LLP will provide a comparison of competing follow-on biologics legislation and demonstrate the major differences between the bills, discuss the potential impact of this legislation on innovator biologics manufacturers, describe how patent challenges to biologics will be different from small molecule drugs, offer practical strategies for building the strongest possible patent portfolios, and provide information on structuring a risk evaluation and mitigation strategy (REMS) for use in keeping a generic competitor off the market. In particular, instructors will discuss:
• The five major differences between patent challenges to drugs and those for biologics;
• Seven methods companies can build into their patent portfolios to maximize protection;
• Risk assessment techniques that prepare you for possible litigation challenges;
• How to use REMS and citizen petitions to fight follow-on biologics; and
• A comparison of the leading legislative proposals and what provisions they have for notification, patent identification, filing of infringement action, and stay-of-approvals.
The registration fee for this webinar ranges from $327 (webinar or audio CD/Transcript alone) to $527 (webinar plus audio CD/Transcript). Those interested in registering for the webcast, can do so here.
Patent Docs is a media partner of this webinar.
Comments